DoD Prostate Cancer, Clinical Consortium Award

The summary for the DoD Prostate Cancer, Clinical Consortium Award grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Dept. of the Army -- USAMRAA, which is the U.S. government agency offering this grant.

DoD Prostate Cancer, Clinical Consortium Award: Summary: The fiscal year 2025 (FY25) Prostate Cancer Research Program (PCRP) Clinical Consortium Award (CCA) provides support to develop, maintain, and enhance the necessary collaborations and resources to rapidly execute phase 2 and/or phase 2-linked phase 1 (phase1/2) prostate cancer clinical trials. The primary intent of the PCRP Clinical Consortium Award is to combine the efforts of leading investigators across multiple institutions to expedite the clinical advancement of novel therapeutic interventions in prostate cancer to decrease the impact of the disease.Distinctive Features:· This award mechanism does not support the development of clinical protocols.· Coordinating Center: This award mechanism supports one coordinating center, which will be responsible for development and maintenance of the consortium organizational structure, and also function as a Clinical Research Site.· Clinical Research Sites: This award mechanism supports multiple clinical research sites, which will be responsible for clinical trial introduction and selection, patient accrual for consortium studies, data collection and timely submissions, meeting attendance, and adherence to the consortium’s operating procedures.